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Inactivated polio vaccine (IPV): background 
•  Poliomyelitis is a potentially fatal infectious disease that can be 
prevented by vaccination 
•  For vaccine efficacy, IPV must be administered in 2-3 bolus injections 
(IM) spread over weeks or months 
 
 
•  Vaccine coverage is hampered in developing countries by difficulties of 
patient access in at-risk populations 
 
!
!McHugh et al. 2015. J Control Release 219:596 
Poly(lactic-co-glycolic acid) (PLGA) microparticles 
for controlled release 
•  Biodegradable polyester 
–  Hydrolytically cleaved at ester linkages 
–  Bulk-degrading 
–  Degradation rate depends on lactide-to-glycolide ratio, molecular weight, and 
formulation parameters 
•  Polymer degradation leads to protein release 
 
IPV encapsulated 
in PLGA matrix 
Burst #1: 
IPV near surface 
(diffusion) 
Burst #2: 
PLGA degrades and forms 
pores that allow IPV release 
Pulsatile release at relevant 
time points can be measured 
from microspheres loaded 
with stable antigens 
Poly(lactic-co-glycolic acid) (PLGA) microparticles 
for controlled release 
•  Biodegradable polyester 
–  Hydrolytically cleaved at ester linkages 
–  Bulk-degrading 
–  Degradation rate depends on lactide-to-glycolide ratio, molecular weight, and 
formulation parameters 
•  Polymer degradation leads to protein release 
•  All 3 serotypes of IPV must survive encapsulation, incubation, and 
release without denaturation 
 
Poly(lactic-co-glycolic acid) (PLGA) microparticles 
for controlled release 
•  Biodegradable polyester 
–  Hydrolytically cleaved at ester linkages 
–  Bulk-degrading 
–  Degradation rate depends on lactide-to-glycolide ratio, molecular weight, and 
formulation parameters 
•  Polymer degradation leads to protein release 
•  All 3 serotypes of IPV must survive encapsulation, incubation, and 
release without denaturation 
 IPV must survive in antigenic 
conformation for weeks/months 
IPV stability: thermostability  


















Type I Type II Type III
-  IPV consists of three serotypes 
(types 1, 2, and 3), which have 
different stability properties 
-  Recovery was calculated from 
the D-antigenicity as measured 
by ELISA 
-  IPV was incubated at 37oC in 
PBS (pH 7.4) buffer 
-  IPV is unstable at elevated 
temperatures, with >50% of 
serotype 1 denatured after 1 
week at 37oC. 
-  All initial thermostability studies 
were done with IPV in aqueous 
solution (not in microspheres) 
Types of excipients 
Sugar Protein Amino acid(s) Ions pH modulator Other 
Sorbitol Gelatin MSG (glutamate) MgCl2 Mg(OH)2 D2O 
Sucrose BSA Arginine Mg(CO)3 
Trehalose Casein Lysine Arginine 
Maltodextrin Methionine EPO 
Inulin Aspartate 
Chitin/chitosan Glutathione 
Vaccine formulations often contain a mixture of multiple excipients. Some of these are 
remnants of the cell culture used for vaccine production, some are added deliberately to 
preserve stability, and some are a combination of the above. 
















Stability after 28 days

























































































































































Sugars on their own did not confer improved stability on IPV during incubation at 37oC. 
 
Sugars performed better when combined with MSG and MgCl2 and also performed better at 
















Stability after 28 days
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Stability after 28 days
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Stability after 28 days
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Stability after 28 days

























































































































































Sugars on their own did not confer improved stability on IPV during incubation at 37oC. 
 
Sugars performed better when combined with MSG and MgCl2 and also performed better at 
















Stability after 28 days
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IPV stability: incubation at 37oC 
After two months of incubation at 37oC, IPV formulation with maltodextrin + MSG + MgCl2 saw 
good recovery of all three serotypes, with 30-60% recovery of type 1 and 40-70% recovery of 
















Stability after 56 days
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Poly(lactic-co-glycolic acid) (PLGA) microparticles 
for controlled release 
•  Biodegradable polyester 
–  Hydrolytically cleaved at ester linkages 
–  Bulk-degrading 
–  Degradation rate depends on lactide-to-glycolide ratio, molecular weight, and 
formulation parameters 
•  Polymer degradation leads to protein release 
•  All 3 serotypes of IPV must survive encapsulation, incubation, and 
release without denaturation 
 
IPV must survive 
drying process 


























Type 3 An aqueous solution of IPV was dried 
under vacuum for 1 hr at room 
temperature. 
 
IPV alone (without added excipients) 
was denatured by drying. 
 
Excipients and excipient combinations 
were added to improve stability. 



















































































































IPV stability:  
Vacuum drying 
Gelatin and sugars both showed 
good results after drying. 
 
Sugars generally showed increased 
protective ability in combination with 
amino acids (glutamate, MSG) and/or 
ions (MgCl2). 
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IPV stability:  
Vacuum drying 
Gelatin and sugars both showed 
good results after drying. 
 
Sugars generally showed increased 
protective ability in combination with 
amino acids (glutamate, MSG) and/or 
ions (MgCl2). 
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Poly(lactic-co-glycolic acid) (PLGA) microparticles 
for controlled release 
•  Biodegradable polyester 
–  Hydrolytically cleaved at ester linkages 
–  Bulk-degrading 
–  Degradation rate depends on lactide-to-glycolide ratio, molecular weight, and 
formulation parameters 
•  Polymer degradation leads to protein release 
•  All 3 serotypes of IPV must survive encapsulation, incubation, and 






IPV stability:  
Emulsification (sonication) 
Gelatin and showed the best 
protection of IPV during the sonication 
step. 
 
Sugars and salts generally had 
minimal effects on the stability during 

























































































































































































IPV stability:  
Emulsification (sonication) 























Stability after 28 days



















































































































































































In vitro cumulative release results are plotted as percentages of the human dose  









































IPV release from PLGA particles 
-  Sugar-based excipients co-encapsulated in PLGA particles promote IPV release 
in two bursts; however, very little later release is seen for types 1 and 3. 


























































































































Gelatin Sucrose, MSG, MgCl2 Maltodextrin, MSG, MgCl2 
5.8 ± 3.6 µ m 10.7 ± 3.4 µ m 11.2 ± 3.4 µ m 
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PLGA microspheres: pH 
•  PLGA degrades into acidic molecules 
•  PLGA degrades by bulk erosion 
–  Acid buildup inside microspheres 
•  pH of release medium (outside particles) over time suggests acid is also building 
up inside particles over time 
 





































Stability after 7 days




•  Water-soluble bases raise the pH of the IPV environment and cause denaturation 
•  Small molecule bases diffuse out of the microparticle faster than the antigen, depleting the 
basic or buffering component before PLGA degradation is completed 
•  Mg(OH)2 is an insoluble base that can be dispersed in the polymer maxtrix 












































































Sucrose (8%), MSG (6.8%), 
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PLGA microspheres: 
Insoluble excipients buffer acidic products 
PLGA microspheres: 
Insoluble excipients buffer acidic products 
•  Cationic polymer Eudragit E PO is insoluble in water at 
neutral pH but soluble at < 3 pH 
–  Basic functional groups raise the local pH of PLGA 
–  The local basic pH accelerates PLGA degradation, 
forming acid components that are buffered by the 
basic Eudragit E 
 
PLGA microspheres: cationic polymers as  
pH-modulating dopants 
-  The amount of Eudragit E in the particles controls the spacing of burst release 
-  The formulations shown above release a total of ~2 human doses spread between 2 
distinct bursts, mimicking multiple bolus injections 
# Human doses released/50 mg 
Burst 
Time (d) 
Type 1 Type 2 Type 3 
0-4 0.92 1.32 0.75 
7-14 0.25 0.62 0.44 
Burst 
Time (d) 
Type 1 Type 2 Type 3 
0-4 1.41 1.09 1.18 
11-21 0.47 0.74 0.55 
# Human doses released/50 mg 
Burst 
Time (d) 
Type 1 Type 2 Type 3 
0-4 1.04 0.80 0.87 
18-28 0.32 0.97 0.52 
# Human doses released/50 mg 
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60% bolus + empty particles
One bolus administration of IPV elicits no 
detectable neutralizing antibodies against 
serotype 1. 
1 dose bolus + empty particles
















IPV Type 1 Neutralizing Antibodies in Serum






1/2 bolus 2x (0, 4 wk)
Two boluses administered 4 weeks apart are 
able to elicit neutralizing antibodies against 
type 1 poliovirus, although the proportion of 
animals protected against the virus decreased 
over time. 
1 dose bolus + empty particles
















IPV Type 1 Neutralizing Antibodies in Serum
1 dose microspheres (F1)






1/2 bolus 2x (0, 4 wk)
1 dose bolus + empty particles
A single injection of IPV-containing 
microspheres (formulation F1) elicits a strong 
neutralizing response immediately after 
injection, without needed a second 
administration. 
 
A single injection of microspheres is equal or 
superior to two bolus injections and appears 
to have even longer duration of immunity. 
1 dose microspheres (F1)
1/3 bolus 2x (0, 8, 16 wk)
1 dose bolus + empty particles
1/2 bolus 2x (0, 4 wk)
















IPV Type 2 Neutralizing Antibodies in Serum
1 dose microspheres (F1)
1/2 bolus 2x (0, 4 wk)






Immunity against type 2, the most stable of 
the antigens, is elicited well by the 
microsphere formulation (red line), matching 
or exceeding the multiple-bolus controls. 
1 dose microspheres (F1)
1/3 bolus 2x (0, 8, 16 wk)
1 dose bolus + empty particles
1/2 bolus 2x (0, 4 wk)
















IPV Type 3 Neutralizing Antibodies in Serum
1 dose microspheres (F1)
1/2 bolus 2x (0, 4 wk)






Interestingly, type 3 stability in the 
microspheres was poorer in vivo than in the 
initial in vitro experiments. 
 
Further stability studies were conducted to 
optimize type 3 stability. 
PLGA microspheres: hydrophilic polycations for 
improved type 3 stability 
-  An optimized concentration of poly(L-lysine) (PLL) improves IPV stability, particularly for 
types 1 and 3. 
-  Higher overall release and higher late type 3 release are observed from microspheres that 
co-encapsulate polycations, such as PLL and low MW polyethylenimine (PEI). 
Burst 
Time (d) 
Type 1 Type 2 Type 3 
0-4 3.2 9.1 3.2 
18-28 2.2 7.7 2.8 

































































































































































































































































2 week titers - type 1
IPV in vivo experiment (next iteration):  
Neutralizing antibodies (2 weeks) 
Type 1: F1 microspheres (red) elicited neutralizing antibodies within 2 weeks, while none of the bolus controls did. The new 
formulation F5 (purple) is superior to F1 at the early time point. 
 
Type 3: The new formulation F5 (purple) is superior to the previous formulation F1 and, importantly, superior to the 
bolus controls. Importantly, the low dose of F5, in which the dosage was calculated by theoretical loading (i.e. 
assuming no loss of IPV doses due to processing or stability) is still superior to all controls and previous 
formulations. 
Summary 
•  Excipients can stabilize IPV against thermal and physical stresses over time 
•  IPV co-encapsulated with stabilizers and pH-modulators can be released in 
a pulsatile manner from PLGA particles 
•  Encapsulated IPV elicits a more potent neutralizing antibody response in 
vivo than free IPV injected as a bolus 
 
•  Expand pulsatile or continuous release platform to other vaccines 
–  Sabin IPV (sIPV), experimental HIV vaccines, etc. 
•  Investigate the effect of types of release kinetics on immune response 
•  Increase the number of pulses that are released in vivo 
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